Emmaus Life Sciences Reports Additional Positive Preliminary Results in Diverticulosis Pilot Trial

–Interim Analysis Indicates Decreased Number of Diverticula and Healthy Tissue–

TORRANCE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) — Emmaus Life Sciences, Inc. (OTCPK: EMMA), a leader in sickle cell disease treatment, announced today preliminary top-line data for two patients who most recently completed the first six months of the scheduled twelve months of treatment in a pilot study of diverticulosis. The study is utilizing the same pharmaceutical-grade L-glutamine (PGLG) oral powder used in Endari® to evaluate the change in the number and size of colonic diverticula and assess safety.